MOR — Morphosys AG Share News
0.000.00%
Last trade - 00:00- €2.53bn
- €2.16bn
- €238.28m
Europe Research Roundup: Believe, Deliveroo, Mondi
Brief: MorphoSys Q4 Revenue EUR 59 Million Vs. IBES Estimate EUR 63.4 Million
Brief: Morphosys Reports Q4 Group Revenue At EUR 59.0 Mln, Down 28%
Brief: Bundeskartellamt - Federal Cartel Office Approves Takeover Of Morophosys AG By Novartis
German competition regulator clears path for Novartis takeover of MorphoSys
Deutsche Boerse says no changes in the German DAX
Europe Research Roundup: Morphosys, Renishaw, Verallia
MorphoSys extends gains as Novartis announces $2.9 bln deal to buy it
Press Digest: Wall Street Journal - Feb 6
Swiss stocks - Factors to watch on February 6
Novartis to acquire cancer drug developer MorphoSys for $2.9 bln (updated)
Brief: Novartis Says Co to Acquire Morphosys AG For EUR 68 Per Share Or An Aggregate Of EUR 2.7Bn In Cash
Brief: Morphosys Says Co Acquired By Novartis For EUR 2.7 Bln Equity Value & Into Purchase Agreement With Incyte For The Sale Of Tafasitamab
Novartis acquires cancer drug developer MorphoSys for $2.9 bln
MorphoSys surges 50% after Reuters report Novartis in acquisition talks
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
Brief: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin
MorphoSys drops after capital increase